Latest Breaking News On - Extracellular vesicle based therapeutic development - Page 1 : comparemela.com

10.08.2022 - -First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Non-Ambulant .

United statesLinda marbRaquel cona shana marinoJoyce allaireNippon shinyaku co ltdLifesci advisorsExchange commission onExtracellular vesicle based therapeutic developmentStrategic communicationsCapricor therapeutics incCapricor company contactRequesting meetingDiscuss next stepsDuchenne muscularPipeline expansion underway using engineeredWebcast today